

# CITATION REPORT

List of articles citing

**Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation**

**DOI: 10.1080/14656566.2016.1267140**

**Expert Opinion on Pharmacotherapy, 2017, 18, 67-77.**

**Source:** <https://exaly.com/paper-pdf/66709675/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 2176-2181	3	14
6	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 251-258	4.1	1
5	[Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies]. <i>Semergen</i> , <b>2018</b> , 44, 323-334	1.9	9
4	Rivaroxaban: searching the integral vascular protection. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 719-728	3.8	7
3	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. <i>Circulation Research</i> , <b>2021</b> , 128, 513-529	15.7	8
2	The Relationship between Atrial Fibrillation and Coronary Artery Disease: Understanding common denominators. <b>2022</b> ,		0
1	Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban. <b>2023</b> , 12,		0